anesthetized open-chest dogs in a constant-pressure coronary E a ndothelin (ET) 1 is a powerful vasoconstrictor of coronary arteries, and several studies have suggested a role for ET in coronary spasm,1.2 atherosclerosis,3'4 and myocardial infarction.5-7 In a previous study,8 we demonstrated that intracoronary ET caused marked vasoconstriction of the coronary circulation and a more pronounced reduction of flow in the subepicardium compared with the subendocardium. However, it remains unclear which ET receptor types are present in the canine coronary circulation and which of these receptors mediated the coronary circulation response to ET. ET-1 appears to elicit its physiological and pathophysiological effects through at least two types of ET receptors in the vasculature. 9 The ETA receptor is selective for ET-1 over ET-3 and is a predominantly smooth muscle cell receptor10'11 that induces vasoconstriction, whereas the ETB receptor is unselective and thought to be endothelium associated, mediating vasorelaxation (for reviews, see References 12 through 14). However, recent studies have suggested that ETB receptors may also be smooth muscle cell receptors that can mediate vasoconstriction. Consequently, the goal of the present study was to determine whether functional ETB receptors mediating vasoconstriction were present in canine coronary arteries. Competition binding assays with radiolabeled ET-1 using the selective ligands BQ-12320 and sarafotoxin S6c21 were performed to distinguish the ETA and ETB receptors and to assess their relative number and affinities. To evaluate the in vivo effects of selective ETB receptor stimulation, sarafotoxin S6c, a highly selective ETB agonist, was administered in anesthetized openchest dogs, and its effects on the coronary vascular bed, including the coronary artery diameter and transmural myocardial blood flow distribution, were assessed in a constant-pressure coronary artery perfusion model. To ensure that the effects of sarafotoxin S6c were due to ETB receptor stimulation, separate experiments were also performed with the selective ETA receptor antagonist BQ-123.
Materials and Methods

ET Receptor Binding Assays
The type, number, and affinities of ET receptors in canine coronary arteries were assessed by competition binding assays on plasma membrane preparations. Pooled left circumflex coronary arteries from five dogs (25 to 30 kg) were used to prepare plasma membranes as previously described. 22 injected intravenously, and the external circuit was primed with 6% dextran, which was pumped into the systemic circulation and replaced by blood from the left femoral artery (see below). The total volume of the perfusion circuit was "200 mL, and the reservoir usually contained ""50 mL. At the end of the experiment, methylene blue was injected into the cannula while the heart was still beating to delineate the vascular territory of the circumflex coronary artery. Immediately after this injection, the heart was arrested by injecting potassium chloride intravenously; it was then removed and fixed in 10% formalin for 3 days. A specimen (:z30 g) of the left ventricular wall was taken from the center of the region of myocardium perfused by the circumflex coronary artery and was cut into three slices of equal thickness. Each slice was cut into three sections, and each section was cut into three portions from endocardium to epicardium. Thus, a total of 27 specimens were counted in a well-type scintillation counter with a germanium crystal (Enertec, Strasbourg, France). Coronary flow per gram of tissue was calculated by multiplying radioactivity per gram of tissue by the ratio of circumflex coronary flow (measured by the flowmeter) to the total radioactivity of the heart. The flows of all the samples in each layer (endocardium, mesocardium, and epicardium) were averaged.
Measurement of Coronary Diameter
The diameter of the circumflex artery was measured continuously27,28 with an ultrasonic dimension gauge (Sonomicrometer 120, Triton Technology, San Diego, Calif). Two 5-MHz piezoelectric crystals were positioned on each side of the coronary artery and attached with suture and tissue adhesive. The cross-sectional area of the coronary artery was calculated by taking into account the external diameter and the wall volume, where the wall volume was calculated as the quotient of mass and density (1.06 g/cm3) of the coronary wall. After the experiment, the wall mass was measured by weighing a known length of the coronary artery excised in the region where the crystals were implanted.
Study Design
The study was performed in three phases. First, ET receptor binding assays were performed on canine circumflex coronary arteries to assess the number and type of ET receptors. These arteries were obtained using anesthesia and surgical procedures identical to those used in the in vivo studies. Competition binding curves were obtained, and one-site Hill plots and IC50s were generated for each ligand. Homologous Analysis of the binding curve data with LIGAND, a curve-fitting program, demonstrated that a three-site model was significantly better than both the one-site (P<.0001) and the two-site (P=.009) models. These results suggest the presence of three ET/sarafotoxin sites (Table 1) , although further detailed work will be required to fully characterize them. The first site is an ET-1 selective (ETA) receptor, with an =400-fold higher affinity for ET-1 than for ET-3. Sarafotoxin S6c binds to this site at only micromolar concentrations, whereas the ETA-specific ligand, BQ-123, binds at nanomolar concentrations. The second site binds ET-1 and ET-3 with equal affinities (referred to as ETBH because of its high affinity) and is thus consistent with an ETB receptor according to current nomenclature. Sarafotoxin S6c also binds with high affinity, although BQ-123 does not appear to bind at the concentrations used in our experiments. The third site is also nonselective for ET-1 and ET-3 (referred to as ETBL because of its relative low affinity compared with the other ETB receptor). Sarafotoxin S6c and BQ-123 bind with equal affinity, although much less potently than either ET-1 or ET-3.
Effects of Sarafotoxin S6c on Coronary Blood Flow and Hemodynamics
The sarafotoxin S6c vehicle produced minimal or no change in coronary flow and no change in any other hemodynamic variable. There were also no significant differences in the variables throughout the time of the study in the control animals. Intracoronary sarafotoxin S6c caused a dose-dependent initial transient increase followed by a pronounced decrease in coronary blood flow (Fig 2) .
The initial increase in coronary flow in response to sarafotoxin S6c started at 10±1 seconds after injection, peaked at 16±1 seconds, and had a duration of 15±3 seconds. The percentage change in coronary flow from the preinjection value at each dose is shown in Fig 3A. An intracoronary dose of 0.3 .g sarafotoxin S6c produced a 51+15 mL/min increase in mean coronary flow, although this transient increase in flow was not associated with changes in any other variable, including coronary artery diameter or myocardial segnental shortening.
Sarafotoxin S6c produced a significant decrease in coronary blood flow with a dose of 0.3 ,ug (Fig 3B) , although no other hemodynamic or myocardial variable was affected by this dose. Intracoronary doses of 1.0 and 3.0 ,g sarafotoxin S6c caused marked decreases in coronary blood flow (-49±+9% and -56±6%, respec- ,. 
Effects of Sarafotoxin S6c on Coronary Arterial Resistance and Myocardial Blood Flow Distribution
The initial increase in coronary flow in response to sarafotoxin S6c was associated with parallel decreases in coronary vascular resistance, although there were no significant changes in the coronary arterial diameter. Microsphere injection was not performed at this phase of the response, and consequently, no assessment of myocardial blood flow distribution during sarafotoxin S6c-induced vasodilation was obtained.
After the administration of 0.3 jig IC sarafotoxin S6c, the resistance of the left circumflex coronary arterial distribution (Fig 5A) increased significantly, although the diameter (Fig 5B) and the cross-sectional area (Fig 5C) of the circumflex artery itself were unchanged. With higher doses, the coronary arterial resistance progressively increased in a dose-dependent manner. Significant decreases in the left circumflex artery diameter occurred with the 1.0 and 3.0 ,gg sarafotoxin S6c doses, and the coronary artery cross-sectional area was decreased by 13.2±6.0% with the 3.0 ,ug dose. Myocardial blood flow (Table 3) was significantly altered by the 1.0 and 3.0 ,g doses with a pronounced decrease in blood flow to all layers of the myocardium of a sufficient magnitude to probably cause transmural contractile dysfunction. At the 3.0 gg dose, endocardial blood flow was decreased to 0.41 mL * g`* min1 (a 55% decrease), whereas the epicardial blood flow was 0.24 mL* g`. min-' (a 71% decrease). Although both of these decreased flows may be sufficient to cause myocardial dysfunction, sarafotoxin S6c also caused a significant alteration in the myocardial blood flow distribution, such that the endocardial to epicardial ratio was increased from 1.01±0.07 to 2.17±0.38 (P<.001). Effects of ET Receptor Antagonism by BQ-123 on Sarafotoxin S6c-Induced Alterations in Hemodynamics BQ-123 infusion at a rate to maintain a constant intracoronary concentration of at least 1 ,umol/L resulted in no significant attenuation of the sarafotoxin S6c-induced coronary artery vasodilation or vasoconstriction. BQ-123 did not change the dose at which the maximal increase in flow occurred (0.1 ,ug sarafotoxin S6c) nor the magnitude of the maximal increase in flow (124±43% without BQ-123 versus 113±44% with BQ-123). ETA receptor antagonism with BQ-123 did not change the sarafotoxin S6c-induced vasoconstriction either; the dose at which the maximal decrease in flow occurred (3.0 gg sarafotoxin S6c) and the magnitude of the maximal decrease in flow (-56+7% without BQ-123 versus -86+5% with BQ-123) were not significantly affected by the presence of BQ-123.
Discussion
The present study demonstrates the presence of a significant population of ETB receptors in the canine left circumflex coronary artery through competition binding experiments. Intracoronary injection of sarafotoxin S6c, a selective ETB agonist, produced dose-dependent biphasic responses in the coronary flow, consisting not only of transient vasodilation but also of pronounced and sustained vasoconstriction of both conduit and resistance coronary arteries with commensurate decrements in myocardial function and arterial blood pressure. This sarafotoxin S6c-induced vasodilation and vasoconstriction were not significantly altered by pretreatment with the ETA receptor antagonist BQ-123.
The results of our competition binding assays in coronary arteries have demonstrated the presence of three ET/sarafotoxin binding sites. The first site was typical of the ETA receptor, with affinities of ET-1 >ET-3-BQ-123>sarafotoxin S6c. Another site (ETBH) was a population of ET receptors to which the ETA-specific ligand BQ-123 did not bind but to which ET-1, ET-3, and sarafotoxin S6c bound with Kds of 13, 73, and 24 pmol/L, respectively. The present studies also suggest the presence of a third binding site, which has properties of a lower-affinity ETB receptor (ETBL), although further studies will need to be performed to fully characterize this site. There have been multiple reports In the hemodynamic experiments, sarafotoxin S6c was used to evaluate the effect of ETB receptor stimulation in the canine coronary circulation. The agonist was administered selectively in the left circumflex coronary artery to avoid systemic effects of the agent. Although at high doses there may be a peripheral effect of intracoronary S6c, this dose would first be diluted twice in the respective ventricular chambers, as well as undergoing clearance by the pulmonary circulation.36 It should also be noted that the decreases in mean arterial pressure induced by the higher doses of sarafotoxin S6c were accompanied by marked decreases in myocardial segmental shortening, decreased dP/dt, and increased left ventricular end-diastolic pressure, suggesting that this systemic response was probably due to myocardial dysfunction. The coronary perfusion pressure was maintained constant to allow assessment of coronary vascular resistance via changes in coronary flow and independent of coronary vascular bed autoregulation28 as well as to directly assess changes in coronary artery diameter independent of alterations induced by fluctuations of mean arterial pressure. Similarly, transmural myocardial blood flow distribution is solely the result of local changes in resistance in this model of constant-pressure coronary artery perfusion. However 
